TNF‐α was used as both targeting and therapeutic agent.[79] Bind‐014 is another nanocarrier based therapeutics which was investigated in phase II clinical trial for patients with non‐small cell lung cancer.[80] Bind‐014 is a polylactic acid (PLA) based nanocarrier system wherein the anticancer drug docetaxel was entrapped. Here, TNF is linked to lung cancer.